BOULDER, CO, March 8, 2021 – AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received $300,000 in funding through a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for AmideBio’s Glucose Responsive Insulin (GRI) program. This funding will further AmideBio’s novel approach to develop a GRI that will eliminate the need for people with diabetes to constantly monitor their blood glucose levels and will reduce secondary complications associated with diabetes.
“Under this grant, we will use our novel computational platform combined with our abilty to rapidly generate high purity peptides to advance several lead GRI candidates and demonstrate their efficacy in animal models of diabetes,” said Pawel Fludzinski, CEO and President of AmideBio. “We are delighted that NIDDK has agreed to fund this pivotal research, the results of which have the potential to impact positively the quality of life for people suffering from diabetes.”
Diabetes has become a global health crisis. Current treatment for diabetes usually requires frequent insulin injections or use of an insulin pump to maintain normal glycemia levels. The total number of insulin-requiring patients today is estimated to be around 150–200 million although many believe this to be a low estimate. Both Type I and Type II diabetic patients have difficulty achieving blood glucose control even with regular monitoring. As a result, most suffer from hypo- and hyperglycemic events and multiple secondary complications including neuropathy, nephropathy and retinopathy which can lead to amputations, dialysis and blindness and for many, an early death. A GRI therapeutic would provide diabetic patients with a life-changing treatment option that could markedly improve health outcomes and so reduce the overall cost of diabetes treatment.
AmideBio has a pipeline of novel biotherapeutics targeting metabolic diseases. This pipeline was generated by leveraging its core competencies in intelligent design of drug candidates together with its proprietary BioPure™ technology which delivers high purity and difficult-to-manufacture peptides of any length with unprecedented purity for the pharmaceutical and biotech industry.